Basal plasma immunoreactive calcitonin in postmenopausal osteoporosis

Area of Science:

• Endocrinology
• Bone Metabolism
• Gerontology

Background:

• Postmenopausal osteoporosis (PM-OP) is a significant health concern.
• Calcitonin (CT) deficiency has been hypothesized as a potential cause of PM-OP.

Purpose of the Study:

• To investigate the role of calcitonin (CT) in the etiology and pathogenesis of postmenopausal osteoporosis (PM-OP).
• To determine if basal calcitonin levels are decreased in women with PM-OP.
• To assess the relationship between calcitonin levels and bone mass changes during CT therapy.

Main Methods:

• Measured basal immunoreactive calcitonin (iCT) using radioimmunoassay (RIA) in 62 PM-OP women and 28 controls.
• Assessed correlations between iCT levels and age, disease severity (compression fractures), serum biochemistry, and total body calcium (TBC).
• Evaluated the relationship between basal iCT and bone mass response (TBC) in 20 PM-OP patients treated with synthetic salmon CT.

Main Results:

• Mean basal iCT levels were not significantly different between PM-OP women and age-matched controls.
• No significant correlations were found between basal iCT and age, disease severity, serum markers, or total body calcium in PM-OP patients.
• Basal iCT levels did not correlate with improvements in bone mass during calcitonin therapy.

Conclusions:

• Basal calcitonin levels are not decreased in women with postmenopausal osteoporosis.
• Circulating calcitonin levels do not appear to influence therapeutic changes in bone mass during CT treatment.
• Calcitonin is unlikely to be a major etiologic or pathogenetic factor in postmenopausal osteoporosis.